Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolR?-targeting ADC

Stock Information for Sutro Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sutro Biopharma Inc.

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
Sutro Biopharma to Participate in Upcoming Investor Conferences
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolR?-targeted ADC, on January 4, 2024
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023
Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.